anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a cosmetic or dermatological aq. dispersion ensuring silky light hair and improving combing and hair setting characteristics by combining a fatty acid ester of sugar or alkyl sugar with a specified cross-linked copolymer of acrylamide. CONSTITUTION: A 4-22C fatty acid mono- and/or di-ester of sugar or 1-4C alkyl sugar which is converted into oxyethylene if necessary and a cross-linked copolymer of acrylamide are incorporated into a physiologically or cosmetically allowable aq. medium to obtain the objective cosmetic or dermatological aq. dispersion for treating hair or skin. The copolymer consists of acrylamide and at least one kind of monomer selected from among ammonium acrylate, partially or entirely neutralized 2-acrylamido-2-methylpropanesulfonic acid and methacryloyloxyethyltrimethylammonium chloride.
Hydrocodone Bitartrate and Acetaminophen Tablets contain hydrocodone, a Schedule II controlled substance. As an opioid, Hydrocodone Bitartrate and Acetaminophen Tablets exposes users to the risks of addiction, abuse, and misuse [see DRUG ABUSE AND DEPENDENCE]. 

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed Hydrocodone Bitartrate and Acetaminophen Tablets. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing Hydrocodone Bitartrate and Acetaminophen Tablets, and monitor all patients receiving Hydrocodone Bitartrate and Acetaminophen Tablets for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as Hydrocodone Bitartrate and Acetaminophen Tablets, but use in such patients necessitates intensive counseling about the risks and proper use of Hydrocodone Bitartrate and Acetaminophen Tablets along with intensive monitoring for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see WARNINGS, Life-Threatening Respiratory Depression; Dosage and Administration, Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose]. 

Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing Hydrocodone Bitartrate and Acetaminophen Tablets. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [see PRECAUTIONS; Information for Patients]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
Hyperuricemia, a major worldwide burden on public hygiene, is closely connected with dietary habits. However, few studies have evaluated the association of dietary diversity with hyperuricemia. To preliminarily reveal the status of a diversified diet in preventing hyperuricemia based on a neighborhood-based, massive-scale cohort in China, a total of 43,493 participants aged 20-74 years old, with no history of hyperuricemia at baseline, were enrolled in the research from April 2016 to December 2019. The Dietary Diversity Score (DDS) was utilized to evaluate the dietary variety and split the participants into the low-, medium-, and high-DDS groups. Information on participants was connected to regional health information systems that acquired data on hyperuricemia instances up to 28 February 2023. Hazard ratios (HRs) and 95% confidence intervals (CIs) were computed by Cox proportional hazards models. Restricted cubic splines (RCS) were implemented to analyze dose-response correlation. A total of 1460 individuals with newly diagnosed hyperuricemia were observed over a median follow-up period of 5.59 years. Compared to the low-DDS group, HRs for the medium- and high-DDS groups were 0.87 (95% CI 0.76-0.99) and 0.80 (95% CI 0.70-0.91) in the fully adjusted model, respectively. The risk of hyperuricemia incidence was reduced by 5% for each 1 unit of DDS increase. A linear correlation of DDS with hyperuricemia emerged and further revealed that the intake of 8-10 broad categories of food could decrease the incidence of hyperuricemia. Our results validate the dietary principle of "food diversification" recommended in guidelines. Conclusions should be applied with caution considering the paucity of related evidence in additional nations.
PURPOSE:To obtain the desired component of blood, by adding a water-soluble polymer to blood, passing the blood mixture continuously through a laminar or tubular path, and separating the components of the blood by the gravitational precipitation effect. CONSTITUTION:In the fractional collection of blood components by the grvitational precipitation effect, 10-25vol% water-soluble polymer (e.g. gelatin or its derivative, dextran, etc.) is added to the blood. The blood mixture is passed through at least one laminar or tubular path (e.g. as shown in the figures), and the flow is changed into a multilayered flow composed of the separated layers of the blood components. The desired layer component is separated from the layers. The water-soluble polymer is preferably the one having a molecular weight of >1,000 to accelerate the coagulation of erythrocytes, and the concentration of the polymer is preferably 1-10wt%. EFFECT:The coagulation of erythrocyte can be accelerated effectively, and the plasma component can be collected in high efficiency.
The invention comprises compounds of the formula <FORM:1076915/C4-C5/1> and their acid addition salts, where R1 is H or CH3, R is CH3 or CH2CH2OH and n is 1-4. The salts may be hydrochlorides.  The compounds wherein R1 is H and R is CH3 are prepared by reacting 1-methylamino-2-nitro-4-amino benzene with a compound of the formula X(CH2)nCONH2, where X is Cl or Br, and hydrolysing the product.  The compounds wherein R and R1 are both H are prepared by methylating the primary amino group of a compound of the formula <FORM:1076915/C4-C5/2> after first protecting one of the hydrogen atoms on the amino group, liberating the protected hydrogen atom and hydrolysing the CONH2 group.  The compounds wherein R1 is CH3 and R is CH2CH2OH are prepared by reacting 1-amino-2-nitro-4-methylamino benzene with a compound of the formula X(CH2)nCONH2, reacting the product with a compound of the formula XCOOCH2CH2X, hydrolysing the CONH2 group and converting the NHCOOCH2CH2X group to NHCH2CH2OH by alkaline hydrolysis.  The compounds wherein R1 is H and R is CH2CH2OH are prepared by acylating the 4-amino group of 1-amino-2-nitro-4-amino benzene, reacting the product with a compound of the formula XCOOCH2CH2X, hydrolysing the group in the 4-position, reacting the product with a compound of the formula X(CH2)nCONH2, hydrolysing the group in the 4-position and converting the NHCOOCH2CH2X group to NHCH2CH2OH by alkaline hydrolysis.ALSO:The invention comprises compounds of the formula <FORM:1076915/C2/1> and their acid addition salts, where R1 is H or CH3, R is CH3 or CH2CH2OH and n is 1-4. The salts may be hydrochlorides.  The compounds wherein R1 is H and R is CH3 are prepared by reacting 1-methylamino-2-nitro-4-amino benzene with a compound of the formula X(CH2)nCONH2, where X is Cl or Br, and hydrolysing the product.  The compounds wherein R and R1 are both H are prepared by methylating the primary amino group of a compound of the formula <FORM:1076915/C2/2> after first protecting one of the hydrogen atoms on the amino group, liberating the protected hydrogen atom and hydrolysing the CONH2 group.  The compounds wherein R1 is CH3 and R is CH2CH2OH are prepared by reacting 1 - amino - 2 - nitro - 4 - methylaminobenzene with a compound of the formula X(CH2)nCONH2, reacting the product with a compound of the formula XCOOCH2CH2X, hydrolysing the CONH2 group and converting the NHCOOCH2CH2X group to NHCH2CH2OH by alkaline hydrolysis.  The compounds wherein R1 is H and R is CH2CH2OH are prepared by acylating the 4-amino group of 1-amino-2-nitro-4-amino benzene, reacting the product with a compound of the formula XCOOCH2 CH2X, hydrolysing the group in the 4-position, reacting the product with a compound of the formula X(CH2)nCONH2, hydrolysing the group in the 4-position and converting the NHCOOCH2 CH2X group to NHCH2CH2OH by alkaline hydrolysis.ALSO:Compositions for dyeing hair contain a compound of the formula <FORM:1076915/D1-D2/1> or an acid addition salt thereof, e.g. a hydrochloride, where R1 is H or CH3, R is CH3 or CH2CH2OH and n is 1-4.  The dyes are preferably applied from an aqueous solution of pH 3-10.  Other dyes may be present in the composition.
Partial responders to protocol #8116 will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will be administered 10 days (10 sessions) of MRI-guided 1 Hz rTMS delivered to the original left temporo-parietal junction (TPJ) target. The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
Each year, approximately 10% of asymptomatic smoldering multiple myeloma (SMM) patients progress to incurable multiple myeloma (MM), a neoplasm of plasma cells causing anemia, bone lesions, increased blood calcium levels and renal damage. Lack of consolidated predictive biomarkers of disease progression makes the selection of SMM candidates to early treatment difficult, and a watch and wait approach is still preferred for these patients. We have recently reported results from a retrospective clinical study showing that SMM patients with higher levels of bone marrow (BM) interleukin-17 (IL-17) were at higher risk to rapidly progress to MM than SMM patients with lower IL-17 levels. Several lines of evidence in autoimmune diseases and cancer link IL-17-producing T lymphocytes (Th17) with the gut microbiota, and evidence exists in patients affected by MM that the gut microbiota impacts disease progression and susceptibility to therapies. Such link has not been investigated in patients affected by SMM.

Goal of this observational, non-interventional study is to demonstrate that in humans a correlation exists between BM levels of IL-17 and composition of the gut microbiota.

Enrolled SMM/MM patients will be analyzed for their bone marrow levels of IL-17 together with the distribution of Th17 cells in their BM and peripheral blood. These analyses will be correlated with analyses of the patients' gut microbiome to identify commensal bacteria potentially involved in Th17 cell expansion. We will seek a direct link between gut microbiota, IL-17 and MM by transplanting mice affected by MM with stool samples from the enrolled SMM/MM patients. We expect a more aggressive disease in avatar mice transplanted with stools from IL-17-high patients when compared to IL-17-low patients. Because samples will be collected both in Italy and in the USA, the study will also allow investigating the impact of additional environmental factors (e.g. Mediterranean versus high-fat diet) on host microbiota and IL-17-driven MM. Thus, primary outcome of the study will be evidence of a correlation between BM levels of IL-17 and the composition of the gut microbiota in patients affected by SMM/MM.

The recruited patients will also be monitored for disease progression or relapse after therapy. The study has no statistical power to define correlates of disease progression in these patients. However, the gut microbiome and the levels of BM IL-17 in SMM patients will be correlated to time to MM progression. Additionally, microbiome and BM IL-17 levels in MM patients eligible for hematopoietic stem cell transplantation (HSCT) will be correlated with response to the induction phase, which is routinely evaluated within 3 months. We expect better responses in patients with low levels of BM IL-17. Additionally, based on recently published experience on the role of enteric microbiome in influencing the HSCT outcomes, we have begun collecting stool samples from MM patients before and after HSCT. Therefore, once we identify patients with early relapse, we will be able to determine if they were colonized with tumor-promoting commensal bacteria following the transplant.
The proposed study aims to address a major research gap in caregiving interventions in the context of intergeneration perspective-taking reappraisals. Adult child caregivers are part of a sandwich generation, involved in actualizing their own goals and coping with social expectations to care for their elderly parents. Dementia caregiving presents a particular challenge in life transition wherein the adult child is parenting his or her parents. With global aging, people living with dementia are rising exponentially. This presents a challenge for sustainable care in Hong Kong and also in countries where public services are developing and the demand for family and intergeneration caregiving is high due to collectivistic concerns. It is hypothesized that reappraising intergeneration relationships through perspective-taking will enhance the well-being of adult-child caregivers. Incorporating both psychological and social perspectives, the study makes a unique contribution to address research gaps by evaluating an integrated model of intervention for dementia caregivers. The conceptual model involves the following components: 1) relational insights; 2) self-reflection to integrate the challenges and benefits in caregiving; 3) interpersonal empathy.

Most caregiving psycho-education programs involve skill training including scheduling pleasant events, communicating with the care recipient and other family members. To test the incremental value of perspective-taking reappraisals, the study involves a two-arm randomized controlled trial of 12 weeks of intervention with two conditions: 1) Perspective Taking Reappraisal and 2) Basic Skill Building. Telephone-administered sessions are integrated with home visits to maximize sustainability and accessibility of the intervention. One hundred fifty-four participants will be recruited and randomized. Primary outcomes are reduced depressive symptoms and enhanced psychological well-being for the caregivers. Secondary outcomes include enhanced social support for caregivers and reduced behavioral problems in the care-recipients. Measures are obtained at baseline Weeks 1 (baseline), 6 and 12 with a follow-up at Week 24. Findings have implications for enhancing sustainable care for older adults in the wider society.
Avoiding physical contact is regarded as one of the safest and most advisable strategies to follow to reduce pathogen spread. The flip side of this approach is that a lack of social interactions may negatively affect other dimensions of health, like induction of immunosuppressive anxiety and depression or preventing interactions of importance with a diversity of microbes, which may be necessary to train our immune system or to maintain its normal levels of activity. These may in turn negatively affect a population's susceptibility to infection and the incidence of severe disease. We suggest that future pandemic modelling may benefit from relying on 'SIR+ models': epidemiological models extended to account for the benefits of social interactions that affect immune resilience. We develop an SIR+ model and discuss which specific interventions may be more effective in balancing the trade-off between minimizing pathogen spread and maximizing other interaction-dependent health benefits. Our SIR+ model reflects the idea that health is not just the mere absence of disease, but rather a state of physical, mental and social well-being that can also be dependent on the same social connections that allow pathogen spread, and the modelling of public health interventions for future pandemics should account for this multidimensionality.
The present invention relates to a herbal composition for treatment of foot corn. The composition is prepared using litsea glutinosa and coconut husk. Take 15 gram maida lakadi (litsea glutinosa). burn it on fire till it turns into coal. Again burn it till white layer is formed on that black coal surface. immediately after that grind it into powder. Sieve fine powder using strainer. powder is black in colour. Further separately take 50 gram dry coconut husk. keep it in a steel utensil and burn it till it is converted into black colour. After that grind it into powder. sieve fine powder using strainer. Thereafter both the prepared preparations dissolving in 95 % of distilled water, 5% of carbopol, 1% of preservative and triethanolamine q.s.. wherein mixing the carbopol with decoction and let it set for 10 minutes then slowly add t.e.a. drop by drop and whisk vigorously with hand blender until desired consistency of gel is obtained. After preparation apply 3 pinch of it on place where foot corn has happened by mixing the preparation in 4-5 drops of coconut oil in morning after bath and plaster it with bandage. Do same process in night before sleeping. Continue the process till get relief.
Preoxygenation for 5 min. Injection of saline iv. after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
Evaluation of Anemia and Iron Stores

Correct and exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding) before initiating JESDUVROQ. Evaluate the iron status in all patients before and during treatment with JESDUVROQ. Administer supplemental iron therapy when serum ferritin is less than 100 ng/ml or when serum transferrin saturation is less than 20%. The majority of patients with CKD will require supplemental iron during the course of therapy.

Liver Testing

Assess serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin prior to initiation of JESDUVROQ. Repeat the liver tests if the patient develops signs or symptoms that could be consistent with liver disease during treatment with JESDUVROQ.
Gene silencing through RNA interference (RNAi) is a promising therapeutic approach for a wide range of disorders, including cancer. Non-viral gene therapy, using specific siRNAs against BCR-ABL1, can be a supportive or alternative measure to traditional chronic myeloid leukemia (CML) tyrosine kinase inhibitor (TKIs) therapies, given the prevalence of clinical TKI resistance. The main challenge for such approaches remains the development of the effective delivery system for siRNA tailored to the specific disease model. The purpose of this study was to examine and compare the efficiency of endosomolytic cell penetrating peptide (CPP) EB1 and PEG2000-decorated cationic liposomes composed of polycationic lipid 1,26-bis(cholest-5-en-3-yloxycarbonylamino)-7,11,16,20-tetraazahexacosane tetrahydrochloride (2Х3) and helper lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) for anti-bcr-abl siRNA delivery into the K562 human CML cell line. We show that both EB1 and 2Х3-DOPE-DSPE-PEG2000 (0.62 % mol.) liposomes effectively deliver siRNA into K562 cells by endocytic mechanisms, and the use of liposomes leads to more effective inhibition of expression of the targeted gene (BCR-ABL1) and cancer cell proliferation. Taken together, these findings suggest that PEG-decorated cationic liposomes mediated siRNA delivery allows an effective antisense suppression of certain oncogenes, and represents a promising new class of therapies for CML.
Infection by human papillomaviruses (HPV) can cause warts and tumors. So far, no small molecule antiviral has been approved for the treatment of infections with this DNA virus, although preclinical studies show activity for nucleosidic compounds, such as 9-(2-phosphonylmethoxy)ethylguanine (PMEG) or cidofovir. This prompted us to test new prodrug versions of the nucleoside analog 3'-azido-2',3'-dideoxythymidine (AZT), known to be active against reverse transcriptases and approved for the treatment of HIV. Here we report the synthesis of an ethylbutyl alaninyl ester phosphosphoramidate prodrug of AZT, dubbed AZAEB, and its activity against HPV, a target not known to be sensitive to AZT. A methyl ester derivative was found to be inactive against this and three other DNA viruses, while the phosphoramidate prodrug AZAEB showed a modest inhibitory effect against HPV types 6, 11, 18 and 31. Our results open up new avenues of study for the treatment of diseases caused by members of the papillomaviridae family.
Levetiracetam extended-release tablets, USP are an antiepileptic drug available as 500 mg, 750 mg and 1,000 mg (white) extended-release tablets, USP for oral administration.

The chemical name of levetiracetam, a single enantiomer, is (αS)-α-ethyl-2-oxo-1-pyrrolidineacetamide, its molecular formula is C8H14N2O2 and its molecular weight is 170.21. Levetiracetam is chemically unrelated to existing antiepileptic drugs (AEDs). It has the following structural formula:

Levetiracetam USP is a white to off-white powder. It is very soluble in water (104.0 g/100 mL). It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane. (Solubility limits are expressed as g/100 mL solvent.)

Levetiracetam extended-release tablets, USP contain the labeled amount of levetiracetam. Inactive ingredients: colloidal silicon dioxide, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol, and titanium dioxide.

The medication is combined with a drug release controlling polymer that provides a drug release at a controlled rate. The biologically inert components of the tablet may occasionally remain intact during GI transit and will be eliminated in the feces as a soft, hydrated mass.

Meets USP Dissolution Test 5.